YEAR-END REPORT JANUARY – DECEMBER 2016 NICOCCINO HOLDING AB (publ)
Nicoccino Holding Development
FORTH QUARTER SUMMARY and YEAR-END Report 2016
The Board of Nicoccino Holding has decided during a transition period of 1-2 year not to release reports in English.
For reference see the reports in Swedish at www.nicoccino.se.
If any questions contact Anders Ulfhielm, CEO.
About Nicoccino and our product
ABOUT THE COMPANY
Nicoccino has developed an innovative and patented nicotine product that after completion of a clinical study will be classified as a medicine for smoking cessation (Nicotine Replacement Therapy – NRT). With a clear classification, regulatory uncertainty will be reduced and new markets will open up that would otherwise not be accessible. Sales to consumers will be managed indirectly through a license model with international partners who are more financially equipped to reach out globally.
In 2014/2015 a commercial test launch was conducted in the UK where Nicoccino™ was sold as a consumer product online, and in retail. This introduction confirmed that the concept works and that there is a great potential for this new type of nicotine product.
In early 2016 a new strategy was formed with an increased focus on creating a product platform that can be used by partners who wish to establish themselves in the market of Nicotine Replacement Therapy (NRT) or want to expand their existing product portfolio. This new strategy has resulted in the prioritization of achieving a drugs classification for when entering partnerships.
Nicoccino has its office located in Täby, outside of Stockholm. The company's shares are listed on Nasdaq Stockholm First North since June 2014 and can be found under the abbreviation NICO.
Remium Nordic AB is the Nicoccino’s certified adviser.
For further information, please visit: www.nicoccino.se/en
ABOUT THE PRODUCT
Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking.
The product is designed to offer smokers an attractive alternative when they want to quit smoking. After a pharmaceutical approval, the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT).
Once the strip is placed under the lip and onto the gum, it delivers a quick and potent nicotine effect. Within a couple of minutes the nicotine has been expended and the film dissolves without leaving any residue in your mouth.
The platform is formulated in Sweden and is the result of over ten years of research and development.
The strip itself is leaf thin and alginate based, about half the size of a stamp. Each dose contains 1 mg of medically classified nicotine, an alginate base (extracted from brown seaweed), as well as natural flavorings and aromas. All additional substances are medically approved.
For more information, visit Nicoccino’s website www.nicoccino.se/en, or contact:
Anders Ulfhielm, CEO Nicoccino Holding AB
+46 70 594 7618
anders.ulfhielm@nicoccino.se
This information is information that Nicoccino Holding AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:00 CET on 24th Feb 2017. The report has to be communicated in Swedish and English. If differences between the versions exist, the Swedish version is pertained.
Anders Ulfhielm, CEO, Nicoccino Holding AB
+46 70 594 7618
anders.ulfhielm@nicoccino.se
Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking.
The product is designed to offer smokers an attractive alternative when they want to quit smoking.
After a pharmaceutical approval, the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT).